Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
7.87
0.00 (0.00%)
At close: May 12, 2025, 4:00 PM
7.85
-0.02 (-0.25%)
After-hours: May 12, 2025, 7:06 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Regulus Therapeutics stock have an average target of 8.50, with a low estimate of 7.00 and a high estimate of 11. The average target predicts an increase of 8.01% from the current stock price of 7.87.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 0 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $9 | Buy → Hold | Downgrades | $9 | +14.36% | May 1, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $7 | Buy → Hold | Downgrades | $7 | -11.05% | Apr 30, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades $8 → $7 | Strong Buy → Hold | Downgrades | $8 → $7 | -11.05% | Apr 30, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $28 → $11 | Strong Buy → Hold | Downgrades | $28 → $11 | +39.77% | Apr 30, 2025 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $3 → $6 | Hold → Buy | Upgrades | $3 → $6 | -23.76% | Mar 27, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.30
from -0.82
EPS Next Year
-1.41
from -1.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 185.6M | ||
| Avg | n/a | n/a | 180.3M | ||
| Low | n/a | n/a | 173.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.99 | -0.71 | 0.60 | ||
| Avg | -1.30 | -1.41 | -1.15 | ||
| Low | -2.19 | -2.77 | -2.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.